- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Americans more likely than others to prefer generics, study finds
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
PITTSBURGH — Generic drug maker Mylan has begun shipping a drug for enlarged prostate, the company said Friday.
Mylan announced the launch of alfuzosin hydrochloride extended-release tablets in the 10-mg strength.
The drug is a generic version of Sanofi's Uroxatral, which had sales of about $241 million during the 12-month period ended in June, according to IMS Health.